GENFIT-ADR (GNFT) Fundamental Analysis & Valuation

NASDAQ:GNFT • US3722791098

4.85 USD
+0.12 (+2.54%)
Last: Nov 19, 2025, 02:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Forecast Earnings Financials Ownership News

This GNFT fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

Fundamental Rating

2

Taking everything into account, GNFT scores 2 out of 10 in our fundamental rating. GNFT was compared to 520 industry peers in the Biotechnology industry. GNFT may be in some trouble as it scores bad on both profitability and health. GNFT does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

2

1. GNFT Profitability Analysis

1.1 Basic Checks

  • In the past year GNFT has reported negative net income.
  • In the past year GNFT has reported a negative cash flow from operations.
  • The reported net income has been mixed in the past 5 years: GNFT reported negative net income in multiple years.
  • In multiple years GNFT reported negative operating cash flow during the last 5 years.
GNFT Yearly Net Income VS EBIT VS OCF VS FCFGNFT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M -100M

1.2 Ratios

  • GNFT has a Return On Assets of -17.89%. This is in the better half of the industry: GNFT outperforms 78.13% of its industry peers.
  • With a Return On Equity value of -73.87%, GNFT perfoms like the industry average, outperforming 54.39% of the companies in the same industry.
Industry RankSector Rank
ROA -17.89%
ROE -73.87%
ROIC N/A
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GNFT Yearly ROA, ROE, ROICGNFT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 -200 400 600

1.3 Margins

  • GNFT's Profit Margin has declined in the last couple of years.
  • GNFT's Operating Margin has declined in the last couple of years.
  • The Gross Margin of GNFT (95.42%) is better than 94.95% of its industry peers.
  • GNFT's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for GNFT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 95.42%
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
GNFT Yearly Profit, Operating, Gross MarginsGNFT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. GNFT Health Analysis

2.1 Basic Checks

  • GNFT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • GNFT has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for GNFT has been increased compared to 5 years ago.
  • GNFT has a worse debt/assets ratio than last year.
GNFT Yearly Shares OutstandingGNFT Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
GNFT Yearly Total Debt VS Total AssetsGNFT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -1.41, we must say that GNFT is in the distress zone and has some risk of bankruptcy.
  • The Altman-Z score of GNFT (-1.41) is comparable to the rest of the industry.
  • A Debt/Equity ratio of 0.09 indicates that GNFT is not too dependend on debt financing.
  • GNFT has a Debt to Equity ratio of 0.09. This is in the lower half of the industry: GNFT underperforms 63.55% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Altman-Z -1.41
ROIC/WACCN/A
WACC7.22%
GNFT Yearly LT Debt VS Equity VS FCFGNFT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

  • GNFT has a Current Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.74, GNFT is in line with its industry, outperforming 44.67% of the companies in the same industry.
  • GNFT has a Quick Ratio of 3.74. This indicates that GNFT is financially healthy and has no problem in meeting its short term obligations.
  • GNFT has a Quick ratio (3.74) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 3.74
Quick Ratio 3.74
GNFT Yearly Current Assets VS Current LiabilitesGNFT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

2

3. GNFT Growth Analysis

3.1 Past

  • The earnings per share for GNFT have decreased strongly by -289.19% in the last year.
  • The earnings per share for GNFT have been decreasing by -70.77% on average. This is quite bad
  • Looking at the last year, GNFT shows a very negative growth in Revenue. The Revenue has decreased by -45.94% in the last year.
  • Measured over the past years, GNFT shows a quite strong growth in Revenue. The Revenue has been growing by 11.61% on average per year.
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%

3.2 Future

  • Based on estimates for the next years, GNFT will show a very negative growth in Earnings Per Share. The EPS will decrease by -29.44% on average per year.
  • GNFT is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -1.86% yearly.
EPS Next Y-192.65%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue Next Year-34.41%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
GNFT Yearly Revenue VS EstimatesGNFT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 50M 100M 150M 200M
GNFT Yearly EPS VS EstimatesGNFT Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 -0.5 -1 -1.5 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. GNFT Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for GNFT. In the last year negative earnings were reported.
  • Also next year GNFT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
GNFT Price Earnings VS Forward Price EarningsGNFT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GNFT Per share dataGNFT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 1

4.3 Compensation for Growth

  • GNFT's earnings are expected to decrease with -45.26% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GNFT Dividend Analysis

5.1 Amount

  • GNFT does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

Find the best dividend stocksShow peers with best dividend

GNFT Fundamentals: All Metrics, Ratios and Statistics

GENFIT-ADR

NASDAQ:GNFT (11/19/2025, 2:00:00 PM)

4.85

+0.12 (+2.54%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-20
Earnings (Next)04-22
Inst Owners0.73%
Inst Owner Change-99.99%
Ins Owners0.18%
Ins Owner ChangeN/A
Market Cap242.51M
Revenue(TTM)45.41M
Net Income(TTM)-38.76M
Analysts90.77
Price Target9.84 (102.89%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-5.43%
PT rev (3m)-8.49%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-766.16%
EPS NY rev (3m)-159.86%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-28.49%
Revenue NY rev (3m)-29.85%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.59
P/FCF N/A
P/OCF N/A
P/B 3.97
P/tB 97.96
EV/EBITDA N/A
EPS(TTM)-0.81
EYN/A
EPS(NY)-0.79
Fwd EYN/A
FCF(TTM)-0.16
FCFYN/A
OCF(TTM)-0.08
OCFYN/A
SpS1.06
BVpS1.22
TBVpS0.05
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -17.89%
ROE -73.87%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 95.42%
FCFM N/A
ROA(3y)-8.87%
ROA(5y)-10.74%
ROE(3y)-21.81%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y-50.59%
OM growth 5YN/A
PM growth 3Y-69.99%
PM growth 5YN/A
GM growth 3Y-0.4%
GM growth 5Y0.52%
F-Score2
Asset Turnover0.21
Health
Industry RankSector Rank
Debt/Equity 0.09
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 188.46%
Cap/Sales 7.33%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.74
Quick Ratio 3.74
Altman-Z -1.41
F-Score2
WACC7.22%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-289.19%
EPS 3Y-70.77%
EPS 5YN/A
EPS Q2Q%-137.74%
EPS Next Y-192.65%
EPS Next 2Y-96.29%
EPS Next 3Y-45.26%
EPS Next 5Y-29.44%
Revenue 1Y (TTM)-45.94%
Revenue growth 3Y-6.06%
Revenue growth 5Y11.61%
Sales Q2Q%-43.21%
Revenue Next Year-34.41%
Revenue Next 2Y-21.93%
Revenue Next 3Y-9.85%
Revenue Next 5Y-1.86%
EBIT growth 1Y-216.85%
EBIT growth 3Y-53.58%
EBIT growth 5YN/A
EBIT Next Year-284.52%
EBIT Next 3Y-33.99%
EBIT Next 5YN/A
FCF growth 1Y87.25%
FCF growth 3Y-47.27%
FCF growth 5YN/A
OCF growth 1Y93.33%
OCF growth 3Y-46.21%
OCF growth 5YN/A

GENFIT-ADR / GNFT FAQ

What is the fundamental rating for GNFT stock?

ChartMill assigns a fundamental rating of 2 / 10 to GNFT.


What is the valuation status for GNFT stock?

ChartMill assigns a valuation rating of 0 / 10 to GENFIT-ADR (GNFT). This can be considered as Overvalued.


Can you provide the profitability details for GENFIT-ADR?

GENFIT-ADR (GNFT) has a profitability rating of 2 / 10.


What is the expected EPS growth for GENFIT-ADR (GNFT) stock?

The Earnings per Share (EPS) of GENFIT-ADR (GNFT) is expected to decline by -192.65% in the next year.